Novo Nordisk warns about risks of unregulated copies of weight loss medications

Novo Nordisk alerts about 10 deaths and 100 hospitalizations from unregulated copies of its Ozempic and Wegovy medications

Gerardo BetancourtApril 1, 2026
Novo Nordisk warns about risks of unregulated copies of weight loss medications

Novo Nordisk, manufacturer of the popular medications Ozempic and Wegovy, has reported ten deaths and over one hundred hospitalizations linked to counterfeit versions of its products. These unregulated versions are being marketed primarily online and in unofficial establishments, which has alarmed the company.

Transform your KOLs into Rockstars of Storytelling 

Rockstars of Storytelling is a step-by-step guide that will allow you to transform your KOLs, Commercial Staff, and Rising Leaders into Inspiring Communicators in just 4 steps.

Best of all, it's free! Download it here.

Concerns about the safety of compounded versions

Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, expressed his concern about the lack of regulation in these alternative medications. "It is disconcerting that people can inject themselves with products that are not regulated or approved," Jorgensen stated, emphasizing the need for stricter oversight.

Although U.S. regulations allow the production of compounded versions when there is a shortage, Novo Nordisk argues that medications like Ozempic and Wegovy are too complex to ensure safety in these versions. The company has requested that the FDA prohibit the manufacturing of compounded copies of these drugs.

Shortage and black market

The popularity of the medications, used both for the treatment of diabetes and weight loss, has led to high demand that generated shortages in the United States. This opened the door to the market for unofficial versions. According to Novo Nordisk, these copies have presented multiple safety issues, evidenced in cases of hospitalizations and deaths.

Impact on regulation

The situation highlights the need to strengthen regulation in the manufacturing and marketing of compounded medications. Furthermore, it raises questions about how to balance access to innovative treatments with patient safety.

This case not only reveals the risks associated with unregulated copies, but also the importance of ensuring that medical treatments are distributed through reliable channels and under strict quality controls.

From good ideas to action

To communicate with charisma and effective leadership, it is essential to overcome the obstacles that limit the expression of powerful ideas.

If you're concerned that your message doesn't land with the necessary force or that your words don't spark that "spark" in your audience, our masterclass "Storyleading: How to Communicate with Charisma, Flare and Spark" is the ideal opportunity.

Register for free and discover how to enhance your communication to inspire and motivate your team!

Get Started

Ready to take the first step?


Schedule a call